

Praveen K Bommareddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7223912/publications.pdf>

Version: 2024-02-01

41
papers

1,808
citations

516561

16
h-index

434063

31
g-index

44
all docs

44
docs citations

44
times ranked

2731
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrating oncolytic viruses in combination cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 498-513.	10.6	448
2	Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 1-15.	3.3	215
3	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1119-1128.	3.3	140
4	Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. <i>Frontiers in Oncology</i> , 2017, 7, 202.	1.3	107
5	MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	97
6	Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. , 2019, 7, 214.		86
7	Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. <i>Oncolmmunology</i> , 2019, 8, e1591875.	2.1	78
8	Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. <i>Nature Cancer</i> , 2020, 1, 923-934.	5.7	67
9	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
10	Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. , 2019, 7, 136.		48
11	Intratumoral Approaches for the Treatment of Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 40-47.	1.0	45
12	Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis. <i>Frontiers in Oncology</i> , 2020, 10, 384.	1.3	45
13	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3829-3838.	0.8	44
14	Sensory-Derived Glutamate Regulates Presynaptic Inhibitory Terminals in Mouse Spinal Cord. <i>Neuron</i> , 2016, 90, 1189-1202.	3.8	40
15	Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (V937) in melanoma patients: Interim results of the CAPRA clinical trial. <i>Cancer Research</i> , 2017, 77, CT026-CT026.	0.4	30
16	Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 155-173.	2.3	29
17	Two roads for oncolytic immunotherapy development. , 2019, 7, 26.		28
18	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. <i>Cell Reports</i> , 2016, 17, 957-965.	2.9	22

#	ARTICLE	IF	CITATIONS
19	Unleashing the therapeutic potential of oncolytic viruses. <i>Journal of Clinical Investigation</i> , 2018, 128, 1258-1260.	3.9	22
20	A Role for Dystonia-Associated Genes in Spinal GABAergic Interneuron Circuitry. <i>Cell Reports</i> , 2017, 21, 666-678.	2.9	21
21	Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 971-980.	4.3	17
22	An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22050-e22050.	0.8	14
23	Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. <i>Oncogene</i> , 2018, 37, 3672-3685.	2.6	13
24	Avelumab and other recent advances in Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 2771-2783.	1.1	11
25	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1483.	1.3	10
26	Misexpression of Ptf1a in Cortical Pyramidal Cells In Vivo Promotes an Inhibitory Peptidergic Identity. <i>Journal of Neuroscience</i> , 2015, 35, 6028-6037.	1.7	9
27	Oncolytic Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 419-430.	0.6	8
28	Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. <i>Cancer Research</i> , 2021, 81, CT139-CT139.	0.4	8
29	Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. <i>Journal of Biological Methods</i> , 2019, 6, e112.	1.0	8
30	422â€¦An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. , 2020, , .		5
31	Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption. <i>Methods in Enzymology</i> , 2020, 635, 167-184.	0.4	4
32	Metastasectomy following incomplete response to high-dose interleukin-2. <i>Journal of Surgical Oncology</i> , 2018, 117, 572-578.	0.8	3
33	Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1) Tj ETQq1 1 0.784314 rgBT /Over activation. <i>Cancer Research</i> , 2021, 81, LB180-LB180.	0.4	3
34	421â€¦Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors. , 2020, , .		3
35	Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. <i>Onc Immunology</i> , 2019, 8, e1571390.	2.1	1
36	Abstract 1917: Immunomodulatory effects of a novel, enhanced potency gibbon ape leukaemia virus (GALV) fusogenic membrane glycoprotein-expressing herpes simplex virus platform with increased efficacy combined with anti PD-1 therapy. , 2021, , .		1

#	ARTICLE	IF	CITATIONS
37	Viral-Based Therapies in Melanoma. , 2019, , 699-715.		0
38	Viral-Based Therapies in Melanoma. , 2019, , 1-17.		0
39	P854â€...Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets. , 2020, , .		0
40	Abstract LB-189: Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. , 2018, , .		0
41	75â€...Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer. , 2020, , .		0